H.C. Wainwright raised the firm’s price target on Axsome Therapeutics to $190 from $180 and keeps a Buy rating on the shares. The company said its late-stage candidate AXS-12 achieved the primary endpoint and significantly reduced the frequency of cataplexy attacks vs. placebo in patients with narcolepsy in the SYMPHONY Phase 3 trial, the analyst tells investors in a research note. The firm increased the probability of approval for AXS-12 to 75% from 60%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics initiates PARADIGM Phase 3 trial of Solriamfetol
- Axsome Therapeutics initiated with an Outperform at Baird